NTBL Key Statistics, Chart & Performance
The current stock price of NTBL is 0.2479 USD. In the past month the price decreased by -45.4%. In the past year, price decreased by -90.85%.
NTBL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About NTBL
Company Profile
Notable Labs Ltd. engages in the development of predictive medicines for patients with cancer. The company is headquartered in Foster City, California and currently employs 16 full-time employees. The company went IPO on 2014-09-30. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Company Info
NOTABLE LABS LTD
320 Hatch Drive
Foster City CALIFORNIA US
Employees: 16
Phone: 14158512410
NOTABLE LABS LTD / NTBL FAQ
What does NOTABLE LABS LTD do?
Notable Labs Ltd. engages in the development of predictive medicines for patients with cancer. The company is headquartered in Foster City, California and currently employs 16 full-time employees. The company went IPO on 2014-09-30. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
What is the stock price of NOTABLE LABS LTD today?
The current stock price of NTBL is 0.2479 USD. The price decreased by -27.68% in the last trading session.
Does NTBL stock pay dividends?
NTBL does not pay a dividend.
What is the ChartMill technical and fundamental rating of NTBL stock?
NTBL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for NOTABLE LABS LTD?
NOTABLE LABS LTD (NTBL) has a market capitalization of 2.39M USD. This makes NTBL a Nano Cap stock.
NTBL Technical Analysis
NTBL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NTBL. NTBL has a bad profitability rating. Also its financial health evaluation is rather negative.
NTBL Financial Highlights
Over the last trailing twelve months NTBL reported a non-GAAP Earnings per Share(EPS) of -6.91. The EPS increased by 65.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.09% | ||
| ROE | -232.9% | ||
| Debt/Equity | 0.03 |
NTBL Forecast & Estimates
8 analysts have analysed NTBL and the average price target is 9.18 USD. This implies a price increase of 3603.11% is expected in the next year compared to the current price of 0.2479.